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Abstract
Osteogenesis imperfecta (OI) is a rare genetic disorder of the connective tissue and 90% of cases are due to dominant
mutations in COL1A1 and COL1A2 genes. To increase OI disease knowledge and contribute to patient follow-up
management, a homogeneous Italian cohort of 364 subjects affected by OI types I–IV was evaluated. The study population
was composed of 262 OI type I, 24 type II, 39 type III, and 39 type IV patients. Three hundred and nine subjects had a type I
collagen affecting function mutations (230 in α1(I) and 79 in α2(I)); no disease-causing changes were noticed in 55 patients.
Compared with previous genotype–phenotype OI correlation studies, additional observations arose: a new effect for α1- and
α2-serine substitutions has been pointed out and heart defects, never considered before, resulted associated to quantitative
mutations (P= 0.043). Moreover, some different findings emerged if compared with previous literature; especially, focusing
the attention on the lethal form, no association with specific collagen regions was found and most of variants localized in the
previously reported “lethal clusters” were causative of OI types I–IV. Some discrepancies have been highlighted also
considering the “50–55 nucleotides rule,” as well as the relationship between specific collagen I mutated region and the
presence of dentinogenesis imperfecta and/or blue sclera. Despite difficulties still present in defining clear rules to predict the
clinical outcome in OI patients, this study provides new pieces for completing the puzzle, also thanks to the inclusion of
clinical signs never considered before and to the large number of OI Italian patients.
Introduction
Osteogenesis imperfecta (OI; MIM#166200, MIM#166210,
MIM#259420, and MIM#166220) is a rare hereditary
connective tissue disorder, with an incidence of ~1:15,000
to 1:20,000 in newborns [1]. The clinical spectrum, char-
acterized by a wide intra- and interfamilial variability, is a
continuum ranging from nearly asymptomatic individuals
with occasional fractures, regular stature, and normal life-
span to phenotypes characterized by severe skeletal fragi-
lity, bone deformities, and significant growth deficiency up
to neonatal lethality. Affected patients may also show a
number of non-skeletal features such as blue sclera, hearing
deficit, dentinogenesis imperfecta (DGI), cardiac defects,
and joint hyperlaxity [2]. The disease is also characterized
by a huge genetic heterogeneity, including autosomal-
dominant, autosomal-recessive, and X-linked forms. About
90% of cases are caused by dominant mutations in COL1A1
(MIM#120150) or COL1A2 (MIM#120160) genes, encod-
ing for α1(I) and α2(I) chains of type I collagen [3]. OI
patients were distinguished in four clinical types according
to clinical signs and radiographic features [4], then updated
with more recent revisions [3]. Type I is the most common
and includes patients with blue sclera and a range of frac-
tures in the absence of bone deformities. OI type II results in
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prenatal or perinatal lethal outcome with severe deformities,
congenital fractures, and marked deficiency of ossification.
Type III is the most severe OI in non-lethal cases, char-
acterized by a very short stature, long bone deformities, and
multiple spinal problems. Lastly, type IV is a moderately
deforming form with a variable phenotypic expression, with
the presence of multiple fractures and white/gray sclera [3].
From a structural point of view, type I collagen is the major
extracellular matrix protein of the bone, skin, tendon, and
ligament. It is a heterotrimer constituted of two α1 chains
and one α2-chain. Each chain has an amino- and a carboxyl-
terminal propeptide at the ends and a central triple helical
domain composed of 338 uninterrupted Gly-X-Y triplets.
Glycine has a key role in collagen organization, as it is the
only amino acid small enough to guarantee the proper
folding of the polypeptide chains. The assembly of pro-α1
and pro-α2-chains into a triple helix begins at the carboxyl-
terminal toward the amino-terminal end [5]. OI type I is
usually caused by nonsense, frameshift, splice site muta-
tions, and by a small number of big rearrangements that
result in a reduced synthesis of structurally normal type I
collagen, referred as a quantitative defect. On the other
hand, OI types II–IV are mostly caused by substitutions of
glycine in the triple helical domain, leading to abnormal
type I collagen molecules that alter the triple helix folding
and the fibrils formation, resulting in a qualitative defect
[5, 6]. So far, more than 1500 COL1A1-A2 distinct variants
have been described in the OI Variant Database [7]. Despite
this, some general rules about the genotype–phenotype
relationship have been recognized [8–12], but all clinical
manifestations have not been investigated yet and no
directions about the wide clinical variability have been
defined, including the different clinical outcome observed in
patients who carry the same DNA change. In the present
study, correlation between the occurrence of clinical man-
ifestations and the type/location of genetic variants in
COL1A1-A2 genes was investigated to describe OI clinical
spectrum in the Italian population and to obtain useful
indications to better predict the evolution of the disease and
the follow-up management.
Subjects and methods
Patients’ dataset
The study population included 364 patients (167 adults, 174
children, and 23 fetuses) from 295 unrelated families,
evaluated between 2008 and 2016. The cutoff of 18 years
was used to divide children and adults. In total, 249 patients
were recruited at the Department of Medical Genetics,
Istituto Ortopedico Rizzoli, Bologna (IOR), and 115 at the
Department of Pediatrics “La Sapienza” University, Rome,
both OI national reference center. Patients were clinically
evaluated by multidisciplinary teams and classified by three
clinicians with a long experience in OI, in accordance to the
Van Dijk and Sillence criteria, and, in particular, to the
described detailed clinical presentation and severity grading
scale [3]. The study includes only individuals with a well-
defined clinical diagnosis of OI types I–IV; patients with no
extraskeletal involvement or with possible alternative
diagnosis were excluded. All genetic, analyses were per-
formed at the Department of Medical Genetics. Personal,
familial, clinical and genetic data were collected and stored
on an IT platform GephCard (Genotype-Phenotype Corre-
lation, Analyses and Research Database) [13], in line with
patient privacy rules, and legal and ethical data protection
requirements. The study was approved by the Ethic Com-
mittee of IOR (ID 0024328/2014) in July 2014 and
informed consent was obtained from all participants.
Clinical features and genotype–phenotype
correlation criteria
OI patients were evaluated for standing height, craniofacial
signs (triangular face, frontal bossing, Wormian bones
(WBs)), DGI, cardiac defects, scleral hue, skin problems,
joint hyperlaxity, lumbar spine bone mineral density
(BMD), and hearing loss. More in details, standing height
was obtained by a stadiometer and only measured in lying
down position for patients not able to stand up. All height
measurements were recorded as means and SD in relation to
age- and sex-specific Italian reference data (Z-score). A
triangular face was defined as a triangular shaped face
contour in frontal view and tapering/narrow chin; frontal
bossing was described as bilateral bulging of the lateral
frontal bone prominences with relative sparing of the mid-
line [14]. The presence of WBs was classified as positive
when the skull radiographs detected ten or more of them.
DGI was considered as an abnormal structure of dentin and
discoloration of teeth, ranging from gray–brown to blue
opalescent. Cardiovascular abnormalities were detected by a
cardiological evaluation in specialized centers. In particular,
a complete transthoracic echocardiography was performed,
including M-mode assessment of left ventricular dimen-
sions and function, two-dimensional imaging, color flow
mapping, and continuous and pulsed-wave Doppler, taking
special care to the morphology and the function of the
atrioventricular and semilunar valves. All detectable regur-
gitations were recorded and divided into mild, moderate, or
severe [15], and only abnormalities from moderate to severe
were included in the study and clustered together. Blue,
gray, and white scleral hue were considered; patients were
classified to have “blue sclera” if the color is Wedgewood
blue [3], whereas they were categorized in “gray sclera” in
case of blurred blue pale or gray. Skin abnormalities, as
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atypical scarring or easy bruising, were clinically evaluated
by a specialist also in relation to the personal history; joint
hyperlaxity was assessed by Beighton score and/or by his-
tory of multiple recurrent dislocations. According to a
recent meta-analysis [16], bisphosphonate treatments were
evaluated as not affecting other features in OI, except for
BMD. To this, BMD from DXA (Dual X-ray Absorpto-
metry) at the lumbar spine (L1–L4) was considered in
children only, as data were collected before the treatment
with anti-fractures drugs. Children were classified as
affected by osteopenia for Z-score value included between
− 1 and − 2, and affected by osteoporosis for value lower
than − 2. To evaluate the presence of hearing loss, a pure
tone audiometry was performed under standard conditions
in a soundproof room; all patients with hearing impairment
(conductive, sensorineural, and mixed) were clustered
together. Variants were grouped in quantitative or qualita-
tive defects, assuming that all nonsense, frameshift, large
rearrangement, and splice site mutations would cause an
haploinsufficiency, whereas glycine substitutions would
lead to type I collagen qualitative alterations [5, 6].
Type I collagen mutations analysis
For each proband, the screening of all coding exons of
COL1A1-A2 genes, including the exon–intron boundaries,
was performed by qPCR with high-resolution melt (HRM)
analysis, using SensiMix HRM kit (Bioline, London, UK)
[5], able to simultaneously identify point mutations and
large deletions/insertions. All amplicons with an abnormal
profile were analyzed by Sanger sequencing (Thermo Fisher
Scientific, Waltham, MA, USA). The sequences obtained
were aligned with the GenBank reference sequences
of COL1A1 gene (NM_000088.3) and COL1A2
(NM_000089.3). DNA alterations were recorded according
to HGVS (Human Genome Variation Society) recommen-
dations (http://varnomen.hgvs.org/). Patients with coding
variants of unknown significance were excluded from
the work. All DNA modifications included in this study
were pathological and deposited into the OI Variant Data-
base (https://oi.gene.le.ac.uk/home.php). In the text, the
terms “mutations” and “affecting function alterations” were
used to refer to a disease-causing change.
Statistical analyses
The entire dataset was considered in all the analyses
according to data availability. Statistical associations were
also repeated considering children and adults separately to
better evaluate potential age-related evolution. All con-
tinuous data were expressed in terms of the mean and the
SD, the categorical data were expressed as frequency and
percentages. The Kolmogorov–Smirnov test was performed
to test normality of continuous variables. The analysis of
variance (ANOVA) test was performed to assess the
between-groups differences of continuous, normally dis-
tributed and homoscedastic data; the Mann–Whitney test
was used otherwise. The ANOVA test followed by the
Scheffè post hoc pairwise comparison was used also to
assess the among-groups differences of continuous, nor-
mally distributed, and homoscedastic data; the Kruskal–
Wallis test followed by the Mann–Whitney test with the
Bonferroni correction for multiple comparison was used
otherwise. Fisher’s χ2-test was performed to investigate the
relationships between dichotomous variables. Pearson’s χ2-
test, evaluated by exact methods for small samples, was
performed to investigate the relationships between catego-
rical variables. Spearman’s rank correlation was used to
assess the relationship between continuous variables; Ken-
dall tau correlation, evaluated by exact methods for small
samples, was used to assess the correlation between ordinal
variables. For all tests, P < 0.05 was considered significant.
All statistical analyses were performed using SPSS v.19.0
(IBM, Corp., Armonk, NY, USA).
Results
Molecular genetics findings
Molecular screening identified a collagen mutation in 309
patients, 230 in α1(I) and 79 in α2(I) (Additional Files 1).
Overall, 114 mutations lead to a qualitative defect (45 in α1,
69 in α2) and 195 to a quantitative alteration (185 in α1, 10
in α2). Considering the collagen structure, 33 subjects
carried a mutation in the N-propeptide, 11 in the C-pro-
peptide, and 265 in the triple helix domain. A total of 187
distinct mutations were identified: 143 distinct point muta-
tions were localized on COL1A1, 42 on COL1A2 gene, and
2 large rearrangements: a deletion of the first six exons of
COL1A1 and a partial deletion of 13–14 COL1A2 exons.
No mutations were found in 55 patients (15.1%), also tested
through NGS panel to exclude the presence of recessive or
X-linked OI forms.
Clinical evaluation and demographic information
The study population consisted of 195 females, 156 males,
and 13 fetuses of unknown gender. According to Van Dijk
and Sillence classification [3], 262 patients were affected by
OI type I (72%), 24 by type II (6.6%), 39 by type III
(10.7%), and 39 by type IV (10.7%). The study cohort
consisted of 174 children (mean age 7.27 ± 4.7 years), 167
adults (mean age 37 ± 12 years), and 23 fetuses. Data on
disease inheritance were available for 274 patients: 158
(57.7%) have a positive family history, whereas 116
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(42.3%) present a sporadic form. A positive family history
is linked to OI type I and IV (detected in 64.8% and 66.7%
of cases, respectively), whereas sporadic forms are related
to OI type II and III (recorded in 77.8% and 81.5% of
patients) (P < 0.0005); of note, the incidence of a positive
familiarity decrease at the increasing of OI severity (Kendal
tau=− 0.258, P < 0.0005).
Genotype–phenotype correlation
The OI clinical types’ distribution, stratified on the gene
involved, is described in Table 1. Concerning the 55 indi-
viduals with a clinical OI diagnosis and a negative screen-
ing result, 70.9% is OI type I, 14.55% OI type III, and
14.55% OI type IV. Quantitative alterations are mainly
responsible for OI type I, whereas qualitative defects are
significantly associated to OI types II–IV (Fig. 1; P <
0.0005), showing an ordinal and increasing correlation with
the severity worsening of the disease (Kendall tau=− 0.25,
P < 0.0005). Analyzing the collagen genes separately, the
ordinal correlation was maintained only for COL1A1 (P <
0.0005). Considering collagen I propeptides, mutations in
the C-terminal domain are always responsible for a non-
lethal disease, frequently causing a mild or moderate phe-
notype (90%). Mutations located in the N-propeptide cover
the full spectrum of OI types, including an OI case with
mild Ehlers–Danlos syndrome (EDS) signs, but resulting
predominantly in OI type I and IV (93.9%). In the α1-C-
propeptide, 6/11 cases (54.5%) had mutations located
within 50–55 nucleotides upstream of the most 3′ exon–
exon junctions or in the last exon of the gene (c.3653delC
and c.3925C > T), not causing protein degradation, as pre-
viously reported [17, 18], but responsible of structural
defects and severe disease forms. On the contrary, c.3807 G
> A described inside this range is causative of mild phe-
notype in 2/2 cases, belonging to the same family. Simi-
larly, c.3727 G > T was 50–55 nucleotides upstream the 3′
exon–exon junction but related to a moderate OI form.
Finally, c.4332dupC, located in the last exon, was identified
both in mild and severe OI cases. Concerning the α2-chain,
the only mutation identified in the C-propeptide located in
the above-mentioned domain is causative of mild OI.
Considering clinical phenotype compared with location of
glycine mutations, a severity gradient from N-terminal to C-
terminal end was identified in both genes (Fig. 2). The
majority of quantitative mutations related to OI type I was
located in the first part of the α-helical domain (exons 7–14
for α1 and exons 8–17 for α2); glycine substitutions related
to OI type II and III were distributed along the entire length
of COL1A1 gene, even if they were more frequent in the
second part of the gene.
Clinical variability
Different clinical outcomes in the presence of a same cau-
sative collagen mutation was evaluated for the 59 genetic
alterations shared by more than one patient (45 in α1; 14 in
α2). Ten out of 45 COL1A1 mutations (5/7 qualitative and
5/38 quantitative defects) and 5 out of 14 COL1A2 disease-
causing changes (all qualitative defects) were related to
clinical class variability (25.4%). In five glycine substitu-
tions [α1-chain: p.(Gly491Ser); p.(Gly560Ser); p.(Gly767-
Ser); α2-chain: p.(Gly193Ser); p.(Gly874Asp)] a variability
ranging from lethal to non-lethal forms was observed.
Considering the intra-familial cases, a different outcome
was observed in 9 out of 36 families (25%), with a disease
worsening in the new generations in 4 of them [α1-chain: p.
(Pro997Leufs*111); p.(Gly491Ser); α2-chain: p.(Gly193-
Ser); p.(Gly874Asp)].
OI lethal form
Twenty-four out of 364 OI cases (6.6%) showed a lethal
form. Specifically, 21 glycine substitutions and 3 different
splice site mutations were detected (Table 2; 16 are novel).
Considering the glycine substitution type, lethal outcomes are
related to charged (Aspartic acid, Glutamic acid, Arginine) or
branched (Valine) amino acids rather than nonpolar (Alanine)
Table 1 Relationship between OI types and mutated genes
Clinical
types
No. of patients
with COL1A1
mutations
No. of patients
with COL1A2
mutations
No. of patients
without
mutation in
collagen I
OI type I 175 (66.8%) 48 (18.3%) 39 (14.9%)
OI type II 15 (62.5%) 9 (37.5%) /
OI type III 20 (51.3%) 11 (28.2%) 8 (20.5%)
OI type
IV
20 (51.3%) 11 (28.2%) 8 (20.5%)
OI: Osteogenesis Imperfecta
Fig. 1 Relationship between OI types I–IV and the type of genetic
mutation (qualitative or quantitative). The frequency has been reported
for each class
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or neutral polar ones (Cysteine and Serine) (30.8% vs. 8.1%;
P= 0.003). Analyzing the collagen genes separately, the
correlation was maintained only for COL1A2 gene (P=
0.01); 88.9% of lethal cases with COL1A2 mutations is
associated to substitutions by charged or branched amino
acids. Concerning COL1A1, lethal mutations are distributed
along the entire length of the α-helical domain, except for one
localized in the N-terminal propeptide. Only one glycine
mutation was detected in a previously reported “lethal cluster”
inside the major ligand-binding region three (MLBR3) [8]; on
the contrary, the non-lethal glycine substitution p.
(Gly974Ala), identified in a OI type III patient, resided in the
“lethal domain” inside the MLBR2 [8]. All COL1A2 lethal
mutations are localized in the helical region from exons 19 to
41. Only four of eight mutations were identified in one of the
eight previously described “lethal domains” [8]. In contrast,
six missense mutations [p.(Gly454Ala); p.(Gly649Asp); p.
(Gly661Cys); p.(Gly661Asp); p.(Gly874Asp); p.(Gly991-
Val)] causative of non-lethal phenotypes were identified
inside the domains 1, 3, and 7. In our dataset, the COL1A2
second domain (range p.Gly541-Gly592) was the only con-
firmed as “lethal cluster.”
OI patients with EDS signs
Our OI cohort was also evaluated for the presence of joint
hypermobility and skin hyperelasticity with easy bruising
and abnormal healing with atrophic or hypertrophic scars.
These features were detected in five patients (1.4%) clini-
cally diagnosed as OI, suggesting an OI/EDS overlap
Fig. 2 Glycine substitutions
distribution along the α1- (a)
and α2-chains (b) in relationship
with the clinical outcome. Each
symbol corresponds to a patient
Table 2 Mutations involved in the lethal outcome
Gene Exon DNA change Protein change
COL1A1 1 c.64 G > C p.(Gly22Arg)
8 c.608 G > A p.(Gly203Asp)
20 c.1353+ 1 G > A /
21 c.1462-2 A > G /
22 c.1471 G >A p.(Gly491Ser)
23 c.1562 G >A p.(Gly521Glu)
25 c.1678G > A p.(Gly560Ser)
25 c.1714G > C p.(Gly572Arg)
26 c.1821+ 4_1821+ 7del /
33_34 c.2299 G >A p.(Gly767Ser)
37 c.2515 G > C p.(Gly839Arg)
42 c.3038 G >A p.(Gly1013Glu)
43 c.3065 G > T p.(Gly1022Val)
45 c.3235 G > C p.(Gly1079Arg)
46 c.3263 G > C p.(Gly1088Ala)
COL1A2 19 c.1027 G >A p.(Gly343Arg)
25 c.1460 G >A p.(Gly487Gu)
26 c.1541 G > T p.(Gly514Val)
29 c.1685G > A p.(Gly562Asp)
30 c.1730G > A p.(Gly577Asp)
31 c.1774G > A p.(Gly592Ser)
38 c.2333 G >A p.(Gly778Asp)
41 c.2621 G >A p.(Gly874Asp)
The five mutations identified in the “lethal clusters” described by
Marini et al. [8] are in bold
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phenotype [19]. In all of these cases, a disease-causing
change in collagen I was identified. An OI type IV subject
carried the multi-exon deletion c.(?_−1)_(543+ 1_544–1)
del in COL1A1 gene. The other cases classified as OI type I
have a mutation within the most N-terminal part of α2(I)
helical domains: c.335 G > T p.(Gly112Val), c.432+ 1 G >
A, and c.910 G > A p.(Gly304Ser).
Stature evaluation
Standing height was evaluated in 291 OI patients (129 males
and 162 females), 148 children, and 143 adults. Subjects with
OI type I (n= 227) have a stature on average − 10,746
compared with − 25,062 for type IV (n= 34) and − 62,418
for type III (n= 30) (P < 0.0005), showing as the median
height tends to significantly decrease with the increasing of
disease severity (P < 0.0005). The relation between OI type III
and short stature was also confirmed considering adults (P <
0.0005) and children (P= 0.001) separately. In addition,
patients with qualitative defects are more associated to
short stature than those with quantitative mutations (− 30,936
vs. − 13,183; P < 0.0005). The presence of a COL1A2
mutation significantly influences the stature (P= 0.003); in
particular, the pairwise comparison showed that subjects with
COL1A2 mutations are lower than those with no mutations
(P= 0.002) or COL1A1 mutations (P= 0.046) (Table 3 and
Additional File 2).
Craniofacial signs
A triangular face was detected in 19% of evaluated patients
(25/131; 10 children and 15 adults). Our results show how it
is a typical OI type III sign (81.3%), whereas it is scarcely
associated with OI type IV (21.7%) and type I (7.6%)
(P < 0.0005). COL1A2 mutations seem to be related to the
development of a triangular face (P= 0.057): 36% of sub-
jects with α2-chain mutations developed a triangular face
vs. 15.3% of those with α1-chain mutations and 14.3% of
those with no mutation. Sixteen percent of evaluated
patients has frontal bossing (37/231; 24 children and 13
adults): 36% of OI type III patients, 21.4% of OI type IV,
and 12.4% of OI type I, associating this feature with OI type
III (P= 0.008). WBs were detected in 20.9% of evaluated
patients (38/182). As expected, this is significantly asso-
ciated with OI type III and IV (40% and 42.1%, respec-
tively), whereas type I patients result less inclined to present
this feature (13.8%) (P < 0.0005; Table 3 and Additional
File 2).
Dentinogenesis imperfecta
The presence of DGI was detected in the 24.5% of eval-
uated patients (58/237), 18 adults, and 40 children. DGI
was detected in 31/184 OI type I patients (16.8%), 14/24
OI type III (58.3%), and 13/29 OI type IV (44.8%), thus
being related to OI type IV and III (P < 0.0005); in parti-
cular, the increasing of clinical severity is related to an
ordinal increment of the number of patients with DGI
(Kendall tau= 0.328, P < 0.0005). In 74.1% of patients
with DGI (43/58), a collagen type I mutation was identi-
fied. Qualitative defects influence the insurgence of DGI
much more than quantitative alterations (35.6% vs. 16.7%;
P= 0.0068). In particular, 21/59 patients with a glycine
substitution developed DGI, mostly characterized by a
glycine to serine replacement (14/21). No patient carrying a
glycine mutation in the first 127 amino acids of the α1(I)
triple helical domain (range p.Gly178-p.Gly305) developed
DGI, which is evident in 8/14 with pathological alterations
Table 3 Clinical characteristics
of our dataset subdivided by OI
types
OI type I OI type II OI type III OI type IV p-Value
Subjects 262 24 39 39 /
Gender M/F 117/145 6/5 18/21 15/24 NS
Familial/sporadic
cases
64.8% (129)/
35.2% (70)
22.2% (4)/
77.8% (14)
18.5% (5)/
81.5% (22)
66.7% (20)/
33.3% (10)
P < 0.0005
Qualitative/
quantitative
25.1%(56)/
74.9% (167)
87.5% (21)/
12.5% (3)
71% (22)/ 29%
(9)
48.4% (15)/
51.6% (16)
P < 0.0005
DGI % 16.8% / 58.3% 44.8% P < 0.0005
Height in z-score − 10,746 / − 62,418 − 25,062 P < 0.0005
Cardiac defects % 23.9% / 19.0% 41.7% NS
Blue sclera % 79.2% / 54.3% 50.0% P < 0.0005
Gray sclera % 9.6% / 22.9% 31.6%
WB % 13.8% / 40.0% 42.1% P < 0.0005
Triangular face % 7.6% / 81.3% 21.7% P < 0.0005
Frontal bossing % 12.4% / 36.0% 21.4% P= 0.008
DGI: Dentinogenesis Imperfecta, OI: Osteogenesis Imperfecta, NS: Not Significant, WB: Wormian Bones
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beyond p.Gly305. In the α2(I) triple helical domain, 1/9
individuals carrying the mutation p.(Gly196Asp) within the
first 121 amino acids (range p.Gly90-p.Gly211) showed
DGI, vs. 12/28 patients with mutations beyond p.Gly211.
All mutations related to dental status alterations (n= 34)
were detected in the helical domain without specific hot-
spots, except for a nonsense in α1-N-propeptide and a
frameshift mutation in α1-C-propeptide (Table 3, Addi-
tional File 2, and Fig. 4).
Cardiac defects
The presence of a cardiac alteration was detected in 25.6%
of evaluated cases (52/203; 21 males and 31 females). The
group included 15 children and 37 adults. Heart problems
were identified more frequently in the adult population
(28.2% vs. 23.8%; P= 0.0015). In details, 48 patients
(23.6%) had a valvulopathy and 4 individuals (1.97%) had
other structural defects; specific cardiovascular diseases
were detailed in Table 4. Considering valvulopathies the
most frequent is mitral regurgitation, 40.4%, whereas the
different types of structural defects are equally represented.
Patients with type-IV OI showed a higher tendency to
develop heart problems compared with other OI forms
(Fig. 3b), even if no significant association was detect (P=
0.13). About the genetic background, cardiovascular
abnormalities resulted more associated to quantitative
alterations compared with structural ones (82.9% vs. 17.1%;
P= 0.043). The same correlation was highlighted
considering only the adult population (39.1% vs. 16.7%;
P= 0.055). Mutations related to cardiac defects were found
dispersed along the two genes, including propeptides’
regions (Table 3 and Additional File 2).
Scleral hue
Data on scleral hue were available for 334 patients, whereof
44 white, 245 blue, and 45 gray. The group included 171
children and 163 adults. The presence of blue sclera is
clinically associated to OI type I (79.2%) and less repre-
sented in OI type IV and type III (50% and 54.3%,
respectively); conversely, gray sclera is more frequent in OI
type IV (31.6%) if compared with type I (9.6%) and type III
(22.9%) (P < 0.0005). The same results emerged when
evaluating adults and children separately (P < 0.0005).
Qualitative alterations are associated to the presence of
white and gray sclera, especially when the mutation is
located in the α2(I) gene, whereas quantitative defects are
related to blue sclera, specifically when located in the α1(I)
gene (P < 0.0005). It is noteworthy that the absence of
collagen mutations is associated to gray sclera (p < 0.0005).
Concerning the α1(I) triple helical domain, glycine sub-
stitutions in the first 154 amino acids (range p.Gly178-p.
Gly332) are related to blue sclera in 13/14 individuals,
whereas mutations beyond p.Gly332 lead to colored sclera
in 12/16 subjects, 7 blue and 5 gray (Table 3, Additional
File 2, and Fig. 4).
Table 4 Types of cardiovascular diseases
Cardiovascular diseases No. of patients
Valvulopathies Total 48
Mitral insufficiency 21
Tricuspid insufficiency 8
Aortic insufficiency 7
Pulmonary insufficiency 4
Mitral prolapse 3
Mitral+ aortic insufficiency 2
Mitral+ tricuspid insufficiency 2
Mitral+ tricuspid+ pulmonary insufficiency 1
Structural defects Total 4
ASD 1
Tetralogy of Fallot 1
PDA 1
LVNC 1
ASD: Atrial Septal Defect, LVNC: Left Ventricular Non-Compaction,
PDA: Patent Ductus Arteriosus
Fig. 3 a Stature distribution in OI types I, III, and IV. b Relationship
between OI clinical classes and the presence/absence of cardiac defects
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Other clinical features
Other clinical features, such as cutis laxa and/or sensitive
skin, joint hypermobility, lumbar spine BMD, and hearing
impairments, were investigated and the results are available
in the Supplementary Materials (Additional File 3).
Glycine substitutions in COL1A1 and COL1A2 genes
Assessing the different amino acid substitutions, glycine to
serine was the most frequently observed (n= 51), followed
by arginine (n= 24) and aspartic acid (n= 14). Considering
the clinical effect, OI type II seems to be associated to Asp
substitutions (P= 0.054), OI type III to α1-Ser substitu-
tions, and OI type I to α2-Ser substitutions (P= 0.007).
Discussion
The genotype–phenotype correlation study, performed by
analyzing the largest Italian cohort ever considered, has
allowed us to obtain precious information on 364 Italian
patients with OI types I–IV analyzed for COL1A1 and
COL1A2 genes. The width of the examined population per-
mitted us to consider, for the first time, all OI clinical forms,
therefore defining the distribution of Italian patients. The
proportion of COL1A1 and COL1A2 mutations is in line with
what already described in previous studies [11, 12], except for
a light increase in number of patients without collagen I
mutations (15.1% vs. 10%) [ref. 3, 6]. In particular, 14.9% of
type I patients resulted negative for COL1A1-A2 mutations.
Considering that they were negative also for OI-related
recessive and X-linked genes, and that patients with no
extraskeletal involvement, with only bone fragility or with
possible alternative diagnosis were excluded from the study,
this suggests that other genes could be involved in the
pathogenesis of the mildest form of the disease. A positive
family history was present in 57.7% of patients, in line with
53% of cases reported in Korean population [20], but quite
different to Chinese, Taiwanese, and another Italian popula-
tion, characterized by a lower percentage (32–33%) of familial
cases [11, 21, 22]. This difference could depend on the sample
size and/or on population variances; other in-depth analysis
would be necessary to clarify the diverse distributions. The
percentage of patients with positive family history decreases
with the increasing of phenotype severity, according to the
hypothesis that the most severe cases related to collagen type I
mutations are de novo [2]. In presence of a same mutation, the
clinical classes variability occurs predominantly for qualitative
defects. In details, the α2-chain mutations are causative of
more variable outcomes than α1-chain mutations, most likely
due to the greater number of glycine mutations identified on
COL1A2 gene. Moreover, only glycine substitutions showed
outcomes ranging from mild to lethal.
We confirmed that quantitative defects are related to
milder phenotypes, whereas qualitative alterations are
responsible for the most severe forms [8, 11, 12]. In parti-
cular, an ordinal correlation between qualitative alterations
frequency and disease worsening was shown for COL1A1,
in line with the heterotrimeric structure of type I collagen,
which requires two α1 chains and only one α2 chain,
increasing the possibility that a qualitative α1 defect could
alter a major number of collagen trimers and thus being
responsible for a worse phenotype [23]. Nevertheless, the
percentage of OI type I patients carrying a qualitative defect
is halfway between previous findings: 25.1% in our study
vs. 32% [ref. 12] and 9% [ref. 8]. Of note, no evident
clinical differences beetwen OI type I patients carrying
qualitative versus quantitative defects were observed. In line
with recent studies [9, 12], it was demonstrated that α1-
serine substitutions are related to OI type III and α2-serine
substitutions to OI type I. Moreover, substitutions in the
first 200 residues was confirmed to be usually non-lethal on
both α1- and α2-chains. Previous studies defined the “50–
55 nucleotides rule,” whereby premature termination
codons located within the last 50–55 base pairs of most 3′’
exon–exon junction or in the last one of collagen genes do
not generate non-mediated decay causing severe
Fig. 4 Dentinogenesis
imperfecta (DGI) and scleral hue
matching to the position of
glycine mutations in COL1A1-
A2 genes. BS+= blue, BS−=
gray/white; gray sclera is shown
by dashed lines
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phenotypes [17, 24]. Symoens et al. [18] evaluated this rule
in collagen I C-propeptide, proving its accuracy in 100% of
cases. In our study, half of the cases follows the “50–55
nucleotides rule,” suggesting the need of further studies on a
larger dataset to properly investigate this topic, as well as to
highlight possible population-related genetic determinants
that could influence this mechanism.
The severity pattern given by glycine substitutions in
COL1A1 gene showed an increase from the N-terminal to
the C-terminal end, reflecting the assembly direction of
collagen trimers [8]. This trend was confirmed for both
genes; in particular, quantitative mutations located in the first
part of the α-helical region are mostly causative of a mild
form, whereas glycine substitutions in the second part of the
genes are more often responsible for OI type II and III. It is
noteworthy that a central zone virtually devoid of structural
defects is present, where mutations probably go unnoticed as
being responsible for too mild or too severe phenotypes.
Focusing the attention on lethal OI condition, all cases are
related to glycine substitutions and splice-site mutations,
proving that nonsense, frameshift mutations, and big rear-
rangements lead to surviving phenotype in 100% of cases.
Differently from what was observed by Steiner et al. [2], no
splice-site mutations beyond exon 25 in α2-chain are related
to lethal outcomes, whereas just 7.7% beyond exon 14 of α1-
chain lead to lethality. Lethal phenotypes are related to gly-
cine substitutions with charged or branched amino acids, in
agreement with Marini et al. [8]. Moreover, we proved a
significant correlation between aspartate substitutions and OI
type II. Referring to the previously reported “lethal clusters”
[8], we confirmed only the range p.Gly541-Gly592 described
in COL1A2. A glycine substitution in the other COL1A1-A2
“lethal domains” was found in eight patients with no-lethal
phenotypes, in line with Rauch et al. [9]. These observations,
important for genetic counseling and prenatal diagnosis,
suggest to better investigate the clusters function.
About height evaluation, OI type IV and III were cor-
related to shorter stature than type I, in agreement with
literature [12]. This was confirmed both for adults and
children, proving that this correlation is maintained inde-
pendently from age [9]. From a molecular point of view,
qualitative defects cause a more severe stature reduction, in
line with other studies [9, 25] and with their worse effect.
For the first time the frequency of patients with triangular
face and frontal bossing in the Italian OI population was
provided (19% and 16%, respectively). The WB percentage
is far below than what was observed in other studies (20.9%
vs. 58–59%) but with a similar distribution and correlation
with the clinical types [26, 27]. Frontal bossing, WBs, and
triangular face resulted to be associated to OI type III
patients, also in the children group; this makes the presence
of craniofacial signs a feature of severe forms. The DGI
prevalence is in line with the existing literature [12, 28, 29],
confirming the association with OI type IV and III, also in
agreement with its relationship with qualitative mutations
[11, 12, 28, 29]. Despite this, 16.7% of non-glycine muta-
tions are related to the onset of DGI, an intermediate value
if compared with Andersson et al. [29] (27%) and with that
reported by Lund et al. [28] and Lindahl et al. [12] (4% and
1.4%, respectively). Lindahl et al. [12] observed that OI
patients without collagen I mutations do not have dental
alterations; on the contrary, in our dataset the 33.3% of this
kind of patients develops DGI, thus associating this feature
also to non-collagen OI types. Concerning missense muta-
tions, the most frequent substitutions related to the presence
of DGI regarded the serine, whereas none arginine sub-
stitution in the α1-chain leads to DGI, different from that
identified by Rauch et al. [9]. Looking at the glycine sub-
stitutions in the first 127 amino acids of α1(I) and within the
first 121 amino acids of α2(I) in the triple helical domain,
we proved that mutations in these regions are related to DGI
absence [9, 12], except for p.(Gly196Asp) in COL1A2 gene.
About heart involvement, no previous genotype–pheno-
type correlation has been described, even if different studies
highlighted that OI patients develop cardiovascular diseases
more frequently than the general population [30–32].
According to our data, 23.6% of OI patients developed val-
vulopathy vs. the 2.5% of the industrialized countries popu-
lation [33, 34]. Moreover, 19.7‰ of OI patients had other
structural cardiac defects, compared with 6.82‰ of the
overall Italian population [35]. These data confirm that
alterations of collagen type I synthesis influence the risk of
cardiovascular defects, especially valvulopathies [31], and for
the first time a correlation with quantitative defects emerged.
As they are usually related to milder OI clinical types, a wider
sample size would be necessary to deeply understand this
relationship. Even if more frequently found in the adults,
cardiac alterations were also detected in children, showing a
not concordant age of onset. In consideration of these
observations, a recurrent follow-up would be advisable to
early identify and to monitor the cardiological phenotype.
Concerning the scleral hue, no clear genetic rules have been
yet defined; our data suggest that the presence of white and
gray sclera is associated to qualitative alterations and to α2(I)
mutations, whereas individuals with blue sclera are related to
quantitative defects and to mutations in α1(I). This is in line
with the mechanism potentially responsible for the blue sclera,
whereby a quantitative reduction of type I collagen causes a
thinner sclera, allowing to see the underlying choroidal veins.
All patients, except one carrying a glycine substitution in the
first 154 amino acids (p.Gly178-p.Gly332) of the α1(I) triple
helical domain, have blue sclera, in line with what was pre-
viously observed [9, 12]. The association between this feature
and clinical type has been confirmed in adults and children,
demonstrating that even in adulthood the link remains sig-
nificant despite the tendency to lose the scleral color with age
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increasing. Data collected about hearing loss, skin alterations,
joint problems, and lumbar spine BMD did not reach any
statistical significance, leaving open questions on these clinical
signs.
In conclusion, the information outlined in this study
gives a better overview of OI disease in a homogeneous
Italian population. New evidences for genetic counseling
have been highlighted, even if inter and intra-familial
clinical variability remains one of the main OI critical issues
to better investigate in the future. Taking advantage of the
notable sample size, we also had the opportunity to evaluate
some clinical signs never considered before. It would
be desirable to invest in these population-related studies to
corroborate the data so far observed and to extend the
research field to other genetic and non-genetic determinants
that could affect OI phenotype.
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